New combo therapy offers hope for advanced cervical cancer patients
NCT ID NCT07472153
First seen Mar 16, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This clinical trial is testing a new treatment approach for people with cervical cancer that has spread, come back, or not gone away after standard treatment. The study combines immunotherapy drugs (PD-1/PD-L1 inhibitors) with chemotherapy, with or without another targeted drug (bevacizumab). The goal is to see if this combination helps patients live longer and shrink their tumors. About 120 adults aged 18-75 are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
N.N. Alexandrov National Caner Centre
RECRUITINGMinsk, Lesnoy, 223040, Belarus
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.